What should a custom peptide synthesis certificate of analysis record?
A usable custom peptide synthesis certificate of analysis is a controlled lot record, not a single purity badge. The header should name the peptide, print the sequence in an unambiguous code, and state modifications that change mass or polarity, including N-terminal acylation, C-terminal amidation, disulfide connectivity and non-proteinogenic residues. It should also state the counterion or salt form, the lot identifier, the analysis date and the responsible laboratory.
Three results must stay separate. Identity is evidence that the covalent structure matches the ordered sequence. Chromatographic purity is the area percent of the main peak under a named HPLC method, at a named wavelength, with named integration rules. Net peptide content is the fraction of the solid that is peptide after water, counterion and, where measured, residual solvent are accounted for. An HPLC area figure near the top of the scale does not mean the vial is nearly all peptide by mass. Treating those quantities as interchangeable invalidates later concentration calculations in a research assay.
Method identifiers belong beside the numbers. Column description, method code, detection wavelength and mass-spectrometry ionisation mode should trace to a method identifier. Acceptance criteria should sit next to each result. Untested attributes, including water, residual trifluoroacetic acid, residual solvent, amino-acid stoichiometry and endotoxin, should be marked not tested. A blank cell is not a pass. State the reporting threshold used to ignore minor peaks. Compare the purchase-order sequence with the certificate sequence residue by residue, including terminal status. A single-residue transposition can still yield a clean main peak and a plausible mass if the wrong sequence was synthesised and then purified.
How should the synthesis route be stated on the certificate?
A custom lot is interpretable only if the certificate, or an attached synthesis note, states the route. Solid-phase peptide synthesis and protease-catalysed peptide synthesis are distinct ways to form amide bonds. Routine laboratory practice does not expect the same impurity pattern from both. Stepwise solid-phase assembly can generate deletion sequences, truncations and incompletely deprotected species. Those species often differ from the target by one residue and may sit close to the main peak. An HPLC purity figure without a related-substances table, relative retention times and a reporting threshold does not show whether those process impurities were resolved.
Chymotrypsin-catalysed peptide synthesis is reported as an enzymatic synthetic route (DOI:10.1111/j.1399-3011.1988.tb00927.x). It is not the same operation as a stepwise resin campaign. The certificate should name the catalyst class or the coupling chemistry, not merely say that the peptide was synthesised. An enzyme-mediated fragment condensation can leave residual protein, a different stereochemical risk at the coupled junction, and fragment-derived impurities instead of single-residue deletions. Neither route name is an acceptance result.
The practical fields that follow are the assembly strategy if disclosed, the coupling and deprotection chemistry the supplier will release, cleavage conditions where they affect side-chain integrity, and the purification method. Crude purity and final purity must not be substituted for each other. A buyer comparing quotations should ask which figure is pre-purification and which figure belongs to the released lot. Trade listings have separated catalogue products, custom synthesis and custom manufacture as distinct commercial lines (DOI:10.1021/cen-09123-ad17). The certificate should state which line the lot belongs to, because a catalogue refill and a one-off custom campaign are not documented in the same way.
How should identity evidence be read beside the purity figure?
Identity on a custom lot is not the same statement as purity. A high area-percent peak can be the wrong peptide if the sequence entered at synthesis was wrong, if a deletion co-eluted, or if a modification mass was mis-assigned. Minimum identity evidence is an observed molecular ion within a stated tolerance of the calculated monoisotopic or average mass, together with the sequence string used for that calculation. Record the mass tolerance beside the observed ion. Where the chain is long, or contains isobaric residues, intact mass alone cannot distinguish leucine from isoleucine. Tandem mass spectrometry fragment coverage should be requested when residue order, not bulk mass, is the research question.
Some custom reports add characterisation beyond mass and HPLC. Synthesis and conformational analysis of salivary proline-rich peptide P-B shows a made-to-sequence peptide reported with conformational data as well as a synthetic description (DOI:10.1002/psc.1297). Proline-rich sequences can populate more than one conformation and can give split or broadened peaks that are not impurities. A certificate that shows extra early peaks should say whether they were assigned as conformers, as diastereomers, or as unrelated substances. Conformational notes do not replace chromatographic purity and do not assign a biological function.
Custom-made peptides are also ordered as analytical reagents. A carbon nanoparticle-peptide fluorescent sensor custom-made for trypsin detection is an example of a peptide component built into a method (DOI:10.1016/j.jpha.2020.08.009). If the order is for a sensor element, calibrant or substrate, the certificate should still carry sequence, mass and purity. An incorrect sequence changes what the method responds to. The certificate documents the reagent lot; it does not validate the assay.
How do catalogue, custom manufacture and GMP lines differ from the lot file?
Trade listings group catalogue products, custom synthesis and custom manufacture as separate offerings (DOI:10.1021/cen-09123-ad17). A further listing adds GMP compliance to that trio (DOI:10.1021/cen-09136-ad03). Those phrases are procurement categories, not analytical results. A laboratory reading a custom peptide synthesis certificate of analysis should treat each phrase as a claim the lot file must support or decline.
Catalogue supply means a standing specification and a repeating product code. The certificate should match that specification, and lot-to-lot differences should appear as results against the same limits. Custom synthesis means the sequence, modification or scale was set by the order. The certificate must echo the order, including sequence, terminals, salt form and the requested purity basis. Custom manufacture implies a longer campaign, often with a fixed process description and batch records. If the seller uses that phrase, expect a batch-record reference or a manufacturing statement, not only an HPLC printout. A missing reference leaves the manufacture claim undocumented.
GMP compliance on a supplier line is a quality-system claim. It does not state the purity, the identity tolerance or the tests performed on the vial in hand. A research-grade certificate can be analytically thorough without being a pharmaceutical batch-release document, and a GMP slogan can sit on a thin file. Compare fields, not slogans. Is there a written specification? Does the chromatogram lot number match the label? Australian procurement should file the certificate with the purchase order and the dispatch record so a later query can reconstruct which document belonged to which vial. Tracked dispatch helps only when that same lot identifier is shared. It does not replace the analytical content of the file.
Which purity, counterion and content figures need reconciling?
Chromatographic purity on a custom synthesis certificate is an area-normalised result. It depends on detection wavelength. Residues without a strong chromophore contribute little at 280 nm and may be under-represented relative to a 214 nm or 220 nm trace. The certificate should name the wavelength used for the reported percent. Related substances should be listed with retention time or relative retention time, area percent, and a label such as identified, unidentified, or below the reporting threshold. A purity statement that cannot be recomputed from the peak table is incomplete.
Counterion is part of content, not a footnote. Trifluoroacetate is common after reversed-phase purification in trifluoroacetic acid mobile phases. Acetate, hydrochloride and other salt forms change the mass fraction that is peptide. If the certificate reports HPLC purity but not counterion identity, vial mass cannot be converted to peptide mass without an assumption. Where ion chromatography, fluorine-19 NMR or a salt-exchange statement is provided, name the method and give the result as a percent or a molar ratio. A qualitative salt-free slogan without data is not a result. Water by Karl Fischer, if tested, adjusts net content. If water was not tested, the certificate should say so.
Acceptance compares a result with a limit, not the visual height of a peak. The limit should state its basis, for example area percent by HPLC at a named wavelength. Orthogonal mass evidence supports peak assignment and is not a second purity percent. Reported purity should match the peak table, identity mass should match the header sequence, and any content figure should use only printed counterion and water results.
How should an Australian laboratory file the custom synthesis package?
A certificate that cannot be retrieved against the correct vial is operationally equivalent to a missing test. File by lot number, not by product name. Custom sequences are often ordered once, so a website title may never match the code on the certificate. Each lot folder should hold the certificate, the chromatogram, the mass spectrum or mass table, the sequence confirmation and the packing list. Results should be attributable to an instrument method and a review step. If the file is a scan, confirm that the lot number is legible on the header and on the chromatogram sample name. Mismatched sample names are a reason to quarantine the file until the supplier clarifies them in writing. Replacing the original PDF without keeping the first issue destroys the audit trail.
The word certificate also appears outside analytical chemistry. Data-driven certificate synthesis, in control engineering, is a mathematical certificate for a dynamical system, not a laboratory certificate of analysis (DOI:10.1016/j.automatica.2025.112798). Work on custom algorithms in Windows Active Directory Certificate Services concerns digital credentials, not peptide lots (DOI:10.14569/ijacsa.2021.0120765). Do not file those papers as lot evidence. The analytical certificate names the peptide, the lot, the methods and the results.
Before a custom lot enters an Australian research inventory, check concordance. Order sequence equals certificate sequence. Label lot equals chromatogram lot. Quarantine the vial until those strings agree. Purity basis and limit are stated. Identity mass sits inside the stated window. Counterion and water are reported or marked not tested. Store the file with the dispatch record. That check assigns no human-use status. It makes the custom peptide synthesis certificate of analysis usable as a research record.
Frequently asked questions
What belongs in the header of a custom peptide synthesis certificate of analysis?
The header should name the peptide, print the full sequence including terminals and modifications, state the counterion, and give the lot identifier, analysis date and testing laboratory. Those fields let a receiving laboratory match the file to the vial. A purity percent without this header cannot be traced. Research certificates document the lot; they do not authorise human use.
Is HPLC area percent the same as net peptide content?
No. HPLC area percent describes the main peak as a share of detected signal under a named method and wavelength. Net peptide content describes how much of the weighed solid is peptide after water, counterion and any measured residual solvent are allowed for. A high area percent can coexist with a much lower peptide mass fraction. The certificate should report the basis of each figure and should not collapse them into one number.
Why does the synthesis route matter on the certificate?
Solid-phase assembly and protease-catalysed coupling are different routes to amide products, and laboratory practice expects different impurity patterns from each. The certificate, or an attached note, should name the route or catalyst class so deletion sequences are not confused with fragment impurities. The route name is not itself a pass result. Crude purity and released-lot purity should also be labelled separately.
Does a GMP line on a supplier listing replace the certificate?
No. Trade listings have grouped catalogue products, custom synthesis, custom manufacture and GMP compliance as commercial descriptions. A GMP phrase is a quality-system claim. It does not state identity tolerance, chromatographic purity, counterion or the tests run on a given vial. Read the lot certificate field by field, and keep it with the purchase order and dispatch record. A slogan is not a result.
How should lot numbers be checked before the file is archived?
Compare three strings: the lot on the vial label, the lot on the certificate header, and the sample name on the chromatogram. They should match. File the certificate, chromatogram, mass result, sequence confirmation and packing list under that lot number, not under a website product name. If a correction arrives, keep the original issue and the written clarification together. Tracked dispatch helps only when the same lot identifier appears on the packing list.
Is conformational analysis a substitute for HPLC purity?
No. A synthesis report may include conformational characterisation alongside the preparation, as in work on a salivary proline-rich peptide. Conformers can split or broaden peaks. The certificate should state whether extra peaks were assigned as conformers or as impurities. Conformational notes do not replace area-percent purity, identity mass or a content figure, and they do not imply any biological outcome.
References
- DOI:10.1111/j.1399-3011.1988.tb00927.x — Chymotrypsin‐catalyzed peptide synthesis — International Journal of Peptide and Protein Research — 1988
- DOI:10.1021/cen-09123-ad17 — Catalog Products | Custom Synthesis | Custom Manufacture — Chemical & Engineering News Archive — 2013
- DOI:10.1021/cen-09136-ad03 — Catalog Products|Custom Synthesis|Custom Manufacture|GMP Compliance — Chemical & Engineering News Archive — 2013
- DOI:10.1002/psc.1297 — Synthesis and conformational analysis of salivary proline‐rich peptide P‐B — Journal of Peptide Science — 2010
- DOI:10.1016/j.jpha.2020.08.009 — A carbon nanoparticle-peptide fluorescent sensor custom-made for simple and sensitive detection of trypsin — Journal of Pharmaceutical Analysis — 2020
- DOI:10.1016/j.automatica.2025.112798 — Data-driven certificate synthesis — Automatica — 2026
- DOI:10.14569/ijacsa.2021.0120765 — Applying Custom Algorithms in Windows Active Directory Certificate Services — International Journal of Advanced Computer Science and Applications — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
